Search research articles
Contact Us
Filters
Showing results (61-70 of 86) with videos related to
Page
of 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2025
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial
Peter A Fasching, Dennis Slamon, Zbigniew Nowecki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2012
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer
Antonio C Wolff, Ann A Lazar, Igor Bondarenko, et al.
JAMA Oncology
|
January 13, 2018
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial
Luca Gianni, Mauro Mansutti, Antonio Anton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2013
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer
José Baselga, Patricia Gómez, Richard Greil, et al.
Frontiers in Oncology
|
February 28, 2022
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
Alberto Ocaña, Jose Ignacio Chacón, Lourdes Calvo, et al.
The Oncologist
|
July 2, 2013
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study
Heather-Jane Au, Wolfgang Eiermann, Nicholas J Robert, et al.
Cancer Medicine
|
March 25, 2018
An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer
Jeffrey L Vacirca, Arlene Chan, Klára Mezei, et al.
Clinical Breast Cancer
|
August 24, 2017
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
José Baselga, Claudio Zamagni, Patricia Gómez, et al.
Breast Cancer Research : BCR
|
October 7, 2024
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, et al.
The New England Journal of Medicine
|
October 14, 2011
Adjuvant trastuzumab in HER2-positive breast cancer
Dennis Slamon, Wolfgang Eiermann, Nicholas Robert, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 86) with videos related to
Sort By:
Page
of 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2025
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial
Peter A Fasching, Dennis Slamon, Zbigniew Nowecki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2012
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer
Antonio C Wolff, Ann A Lazar, Igor Bondarenko, et al.
JAMA Oncology
|
January 13, 2018
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial
Luca Gianni, Mauro Mansutti, Antonio Anton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2013
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer
José Baselga, Patricia Gómez, Richard Greil, et al.
Frontiers in Oncology
|
February 28, 2022
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
Alberto Ocaña, Jose Ignacio Chacón, Lourdes Calvo, et al.
The Oncologist
|
July 2, 2013
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study
Heather-Jane Au, Wolfgang Eiermann, Nicholas J Robert, et al.
Cancer Medicine
|
March 25, 2018
An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer
Jeffrey L Vacirca, Arlene Chan, Klára Mezei, et al.
Clinical Breast Cancer
|
August 24, 2017
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
José Baselga, Claudio Zamagni, Patricia Gómez, et al.
Breast Cancer Research : BCR
|
October 7, 2024
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, et al.
The New England Journal of Medicine
|
October 14, 2011
Adjuvant trastuzumab in HER2-positive breast cancer
Dennis Slamon, Wolfgang Eiermann, Nicholas Robert, et al.
Page
of 9